Management still incompetent. Company not advancing squat clinically. Will need to dilute again in relatively short time horizon. Have not demonstrated business model viability. Those hurdles and their effervescent history make it difficult to price in the potential, achievements, results of the platform.
Any changes to the above, there is definitely plenty of room on the upside.
Historically, the spread between ibio and medicago never so large, though its hard to say that the change in price of one explains any portion of the change in price of another.